|
1
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McGuire S: World Cancer Report 2014.
Geneva, Switzerland: World Health Organization, International
Agency for Research on Cancer, WHO Press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lopez PM, Villanueva A and Llovet JM:
Systematic review: Evidencx10-based management of hepatocellular
carcinoma-an updated analysis of randomized controlled trials.
Aliment Pharmacol Ther. 23:1535–1547. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaiser K, Mallick R, Butt Z, Mulcahy MF,
Benson AB and Cella D: Important and relevant symptoms including
pain concerns in hepatocellular carcinoma (HCC): A patient
interview study. Support Care Cancer. 22:919–926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ji Z, Meng G, Huang D, Yue X and Wang B:
NMFBFS: A NMF-based feature selection method in identifying pivotal
clinical symptoms of hepatocellular carcinoma. Comput Math Methods
Med. 2015:8469422015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paul SB, Shalimar, Sreenivas V,
Gamanagatti SR, Sharma H, Dhamija E and Acharya SK: Incidence and
risk factors of hepatocellular carcinoma in patients with hepatic
venous outflow tract obstruction. Aliment Pharmacol Ther.
41:961–971. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rong G, Wang H, Bowlus CL, Wang C, Lu Y,
Zeng Z, Qu J, Lou M, Chen Y, An L, et al: Incidence and risk
factors for hepatocellular carcinoma in primary biliary cirrhosis.
Clin Rev Allergy Immunol. 48:132–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toyoda H, Kumada T, Tada T, Kiriyama S,
Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S and Ito T: Risk
factors of hepatocellular carcinoma development in non-cirrhotic
patients with sustained virologic response for chronic hepatitis C
virus infection. J Gastroenterol Hepatol. 30:1183–1189. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang XX, Wang LF, Jin L, Li YY, Hao SL,
Shi YC, Zeng QL, Li ZW, Zhang Z, Lau GK and Wang FS: Primary
biliary cirrhosis-associated hepatocellular carcinoma in Chinese
patients: Incidence and risk factors. World J Gastroenterol.
21:3554–3563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sacco R, Gadaleta-Caldarola G, Galati G,
Lombardi G, Mazza G and Cabibbo G: EASL HCC summit: Liver cancer
management. Future Oncol. 10:1129–1132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fitzmorris P, Shoreibah M, Anand BS and
Singal AK: Management of hepatocellular carcinoma. J Cancer Res
Clin Oncol. 141:861–876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park JW, Chen M, Colombo M, Roberts LR,
Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS and
Sherman M: Global patterns of hepatocellular carcinoma management
from diagnosis to death: The BRIDGE Study. Liver Int. 35:2155–2166.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scaggiante B, Farra R, Dapas B, Baj G,
Pozzato G, Grassi M, Zanconati F and Grassi G: Aptamer targeting of
the elongation factor 1A impairs hepatocarcinoma cells viability
and potentiates bortezomib and idarubicin effects. Int J Pharm.
506:268–279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alter MJ: Epidemiology of hepatitis C
virus infection. World J Gastroenterol. 13:2436–2441. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smith DW, Frankel LR, Mathers LH, Tang AT,
Ariagno RL and Prober CG: A controlled trial of aerosolized
ribavirin in infants receiving mechanical ventilation for severe
respiratory syncytial virus infection. N Engl J Med. 325:24–29.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harada N, Hiramatsu N, Oze T, Morishita N,
Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y,
et al: Risk factors for hepatocellular carcinoma in hepatitis C
patients with normal alanine aminotransferase treated with
pegylated interferon and ribavirin. J Viral Hepat. 21:357–365.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ
and Lai MS: Treatment of patients with dual hepatitis C and B by
peginterferon alpha and ribavirin reduced risk of hepatocellular
carcinoma and mortality. Gut. 63:506–514. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Honda T, Ishigami M, Masuda H, Ishizu Y,
Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Nakano I, Ishikawa T, et
al: Effect of peginterferon alfa-2b and ribavirin on hepatocellular
carcinoma prevention in older patients with chronic hepatitis C. J
Gastroenterol Hepatol. 30:321–328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krastev Z, Jelev D, Antonov K, Petkova T,
Atanasova E, Zheleva N, Tomov B, Boyanova Y and Mateva L:
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in
cirrhosis after complete destruction of hepatocellular carcinoma.
World J Gastroenterol. 22:2630–2635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thomas E, Feld JJ, Li Q, Hu Z, Fried MW
and Liang TJ: Ribavirin potentiates interferon action by augmenting
interferon-stimulated gene induction in hepatitis C virus cell
culture models. Hepatology. 53:32–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Burchard J, Zhang C, Liu AM, Poon RT, Lee
NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al:
microRNA-122 as a regulator of mitochondrial metabolic gene network
in hepatocellular carcinoma. Mol Syst Biol. 6:4022010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu AM, Yao TJ, Wang W, Wong KF, Lee NP,
Fan ST, Poon RT, Gao C and Luk JM: Circulating miR-15b and miR-130b
in serum as potential markers for detecting hepatocellular
carcinoma: A retrospective cohort study. BMJ Open. 2:e0008252012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Diboun I, Wernisch L, Orengo CA and
Koltzenburg M: Microarray analysis after RNA amplification can
detect pronounced differences in gene expression using limma. BMC
Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smith CA, Smith G and Wolf CR: Genetic
polymorphisms in xenobiotic metabolism. Eur J Cancer.
30A:1921–1935. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Agundez JA, Olivera M, Ladero JM,
Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA and Benítez
J: Increased risk for hepatocellular carcinoma in NAT2-slow
acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics.
6:501–512. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Farker K, Schotte U, Scheele J and
Hoffmann A: Impact of N-acetyltransferase polymorphism (NAT2) in
hepatocellular carcinoma (HCC)-an investigation in a department of
surgical medicine. Exp Toxicol Pathol. 54:387–391. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang J, Xu F and Ouyang C: Joint effect
of polymorphism in the N-acetyltransferase 2 gene and smoking on
hepatocellular carcinoma. Tumour Biol. 33:1059–1063. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Farker K, Schotte U, Scheele J and
Hoffmann A: Assessment of frequencies of lifestyle factors and
polymorphisms of drug-metabolizing enzymes (NAT2, CYP2E1) in human
hepatocellular carcinoma (HCC) patients in a department of surgical
medicinx10-a pilot investigation. Int J Clin Pharmacol Ther.
40:120–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang YS, Chern HD, Wu JC, Chao Y, Huang
YH, Chang FY and Lee SD: Polymorphism of the N-acetyltransferase 2
gene, red meat intake, and the susceptibility of hepatocellular
carcinoma. Am J Gastroenterol. 98:1417–1422. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blum HE: Hepatocellular carcinoma:
Susceptibility markers. IARC Sci Publ. 154:241–244. 2001.PubMed/NCBI
|
|
35
|
Gelatti U, Covolo L, Talamini R, Tagger A,
Barbone F, Martelli C, Cremaschini F, Franceschi S, Ribero ML,
Garte S, et al: N-Acetyltransferasx10-2, glutathione S-transferase
M1 and T1 genetic polymorphisms, cigarette smoking and
hepatocellular carcinoma: A casx10-control study. Int J Cancer.
115:301–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu B, Wang F, Song C, Sun Z, Cheng K, Tan
Y, Wang H and Zou H: Largx10-scale proteome quantification of
hepatocellular carcinoma tissues by a three-dimensional liquid
chromatography strategy integrated with sample preparation. J
Proteome Res. 13:3645–3654. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gütgemann I, Lehman NL, Jackson PK and
Longacre TA: Emi1 protein accumulation implicates misregulation of
the anaphase promoting complex/cyclosome pathway in ovarian clear
cell carcinoma. Mod Pathol. 21:445–454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu
C, Shen A, Wang Y, Li C, Yuan Q, et al: Early mitotic inhibitor-1,
an anaphasx10-promoting complex/cyclosome inhibitor, can control
tumor cell proliferation in hepatocellular carcinoma: Correlation
with Skp2 stability and degradation of p27(Kip1). Human Pathol.
44:365–373. 2013. View Article : Google Scholar
|
|
39
|
Feng YM, Feng CW, Chen SY, Hsieh HY, Chen
YH and Hsu CD: Cyproheptadine, an antihistaminic drug, inhibits
proliferation of hepatocellular carcinoma cells by blocking cell
cycle progression through the activation of P38 MAP kinase. BMC
Cancer. 15:1342015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Z, Wei W, Sun CK, Chua MS and So S:
Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells
inhibits cell cycle progression and cell growth. Liver Int.
35:1403–1415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deng L, Yang J, Chen H, Ma B, Pan K, Su C,
Xu F and Zhang J: Knockdown of TMEM16A suppressed MAPK and
inhibited cell proliferation and migration in hepatocellular
carcinoma. Onco Targets Ther. 9:325–333. 2016.PubMed/NCBI
|
|
42
|
Milovanovic P, Rakocevic Z, Djonic D,
Zivkovic V, Hahn M, Nikolic S, Amling M, Busse B and Djuric M:
Nano-structural, compositional and micro-architectural signs of
cortical bone fragility at the superolateral femoral neck in
elderly hip fracture patients vs. healthy aged controls. Exp
Gerontol. 55:19–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wilson JM, Kunnimalaiyaan S, Gamblin TC
and Kunnimalaiyaan M: MK2206 inhibits hepatocellular carcinoma
cellular proliferation via induction of apoptosis and cell cycle
arrest. J Surg Res. 191:280–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jiang W, Huang H, Ding L, Zhu P, Saiyin H,
Ji G, Zuo J, Han D, Pan Y, Ding D, et al: Regulation of cell cycle
of hepatocellular carcinoma by NF90 through modulation of cyclin E1
mRNA stability. Oncogene. 34:4460–4470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu YS, Tsai YL, Yeh YL, Chung LC, Wen SY,
Kuo CH, Lin YM, Padma VV, Kumar VB and Huang CY: Cell cycle
regulation in the estrogen receptor beta (ESR2)-overexpressing
hep3b hepatocellular carcinoma cell line. Chin J Physiol.
58:134–140. 2015.PubMed/NCBI
|
|
46
|
Meng X, Franklin DA, Dong J and Zhang Y:
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res.
74:7161–7167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sun J, Wang B and Liu Y, Zhang L, Ma A,
Yang Z, Ji Y and Liu Y: Transcription factor KLF9 suppresses the
growth of hepatocellular carcinoma cells in vivo and positively
regulates p53 expression. Cancer Lett. 355:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li X, Yu J, Brock MV, Tao Q, Herman JG,
Liang P and Guo M: Epigenetic silencing of BCL6B inactivates p53
signaling and causes human hepatocellular carcinoma cell resist to
5-FU. Oncotarget. 6:11547–11560. 2015.PubMed/NCBI
|
|
49
|
Wang P, Cui J, Wen J, Guo Y, Zhang L and
Chen X: Cisplatin induces HepG2 cell cycle arrest through targeting
specific long noncoding RNAs and the p53 signaling pathway. Oncol
Lett. 12:4605–4612. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Baik SH, Lee J, Lee YS, Jang JY and Kim
CW: ANT2 shRNA downregulates miR-19a and miR-96 through the
PI3K/Akt pathway and suppresses tumor growth in hepatocellular
carcinoma cells. Exp Mol Med. 48:e2222016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang TH, Yeh CT, Ho JY, Ng KF and Chen TC:
OncomiR miR-96 and miR-182 promote cell proliferation and invasion
through targeting ephrinA5 in hepatocellular carcinoma. Mol
Carcinog. 55:366–375. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen Y, Dong X, Yu D and Wang X: Serum
miR-96 is a promising biomarker for hepatocellular carcinoma in
patients with chronic hepatitis B virus infection. Int J Clin Exp
Med. 8:18462–18468. 2015.PubMed/NCBI
|
|
53
|
Liu Y, Wu C, Wang Y, Wen S, Wang J, Chen
Z, He Q and Feng D: MicroRNA-145 inhibits cell proliferation by
directly targeting ADAM17 in hepatocellular carcinoma. Oncol Rep.
32:1923–1930. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ding W, Tan H, Zhao C, Li X, Li Z, Jiang
C, Zhang Y and Wang L: MiR-145 suppresses cell proliferation and
motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour
Biol. 37:6255–6260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ju BL, Chen YB, Zhang WY, Yu CH, Zhu DQ
and Jin J: miR-145 regulates chemoresistance in hepatocellular
carcinoma via epithelial mesenchymal transition. Cell Mol Biol
(Noisy-le-grand). 61:12–16. 2015.PubMed/NCBI
|
|
56
|
Wang G, Zhu S, Gu Y, Chen Q, Liu X and Fu
H: MicroRNA-145 and MicroRNA-133a Inhibited proliferation,
migration, and invasion, while promoted apoptosis in hepatocellular
carcinoma cells via targeting FSCN1. Dig Dis Sci. 60:3044–3052.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J,
Qin Y, Sun Z and Zheng X: miR-183 inhibits TGF-beta1-induced
apoptosis by downregulation of PDCD4 expression in human
hepatocellular carcinoma cells. BMC Cancer. 10:3542010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liang Z, Gao Y, Shi W, Zhai D, Li S, Jing
L, Guo H, Liu T, Wang Y and Du Z: Expression and significance of
microRNA-183 in hepatocellular carcinoma. ScientificWorldJournal.
2013:3818742013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li ZB, Li ZZ, Li L, Chu HT and Jia M:
MiR-21 and miR-183 can simultaneously target SOCS6 and modulate
growth and invasion of hepatocellular carcinoma (HCC) cells. Eur
Rev Med Pharmacol Sci. 19:3208–3217. 2015.PubMed/NCBI
|
